393
Views
3
CrossRef citations to date
0
Altmetric
Clinical Features - Original Research

Real-world misuse, abuse, and dependence of abuse-deterrent versus non-abuse-deterrent extended-release morphine in Medicaid non-cancer patients

, , , , , , , , & show all
Pages 225-229 | Received 08 Aug 2018, Accepted 19 Feb 2019, Published online: 19 Mar 2019

References

  • National Safety Council. Prescription Nation 2016: Addressing America’s Drug Epidemic. 2016. [cited 2017 Nov 14]. Available from: http://www.nsc.org/RxDrugOverdoseDocuments/Prescription-Nation-2016-American-Drug-Epidemic.pdf.
  • Centers for Disease Control and Prevention. Opioid Overdose. Prescription Opioid Overdose Data. 2016. [cited 2018 Mar 20]. Available from: https://www.cdc.gov/drugoverdose/data/overdose.html.
  • Butler SF, Cassidy TA, Chilcoat H, et al. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. J Pain. 2013;14:351–358.
  • Vietri J, Joshi AV, Barsdorf AI, et al. Prescription opioid abuse and tampering in the United States: results of a self-report survey. Pain Med. 2014;15:2064–2074.
  • Surratt H, Kurtz SP, Cicero TJ. Alternate routes of administration and risk for HIV among prescription opioid abusers. J Addict Dis. 2011;30:334–341.
  • Bucher Bartelson B, Le Lait MC, Dart R, et al. Medical outcomes associated with unintended routes of prescription opioid abuse. Postgrad Med. 2015;127:S54–55.
  • Food and Drug Administration. Abuse-Deterrent Opioids – Evaluation and Labeling. Guidance for Industry. 2015. [cited 2018 Mar 20]. Available from: https://www.fda.gov/downloads/Drugs/Guidances/UCM334743.pdf.
  • Califf RM, Woodcock J, Ostroff S. A proactive response to prescription opioid abuse. N Engl J Med. 2016;374:1480–1485.
  • Rossiter LF, Kirson NY, Shei A, et al. Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US. J Med Econ. 2014;17:279–287.
  • Coplan PM, Kale H, Sandstrom L, et al. Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics. Pharmacoepidemiol Drug Saf. 2013;22:1274–1282.
  • Coplan P, Kadakia A. Changes in diagnosed addiction rates in patients prescribed opioids after introduction of oxycontin with abuse-deterrent properties. College on Problems of Drug Dependence. 77th Annual Meeting:34. 2015.
  • Severtson SG, Bartelson BB, Davis JM, et al. Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010. J Pain. 2013;14:1122–1130.
  • Chilcoat H, Coplan P, Sessler N, et al. Impact of an opioid reformulation with abuse-deterrent properties on doctor-shopping. J Pain. 2014;15:S10.
  • Dart RC, Surratt HL, Cicero TJ, et al. Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med. 2015;372:241–248.
  • Cicero TJ, Ellis MS. Abuse-deterrent formulations and the prescription opioid abuse epidemic in the United States: lessons learned from oxycontin. JAMA Psychiatry. 2015;72:424–430.
  • Dart RC, Iwanicki JL, Dasgupta N, et al. Do abuse deterrent opioid formulations work? J Opioid Manag. 2017;13:365–378.
  • Lebin JA, Murphy DL, Severtson SG, et al. Scoring the best deal: quantity discounts and street price variation of diverted oxycodone and oxymorphone. Pharmacoepidemiol Drug Saf. 2018.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.